<- Go Home
iCAD, Inc.
iCAD, Inc. engages in the provision of cancer detection and therapy solutions in the United States. It operates through two segments, Detection and Therapy. The company provides ProFound AI for digital breast tomosynthesis and 2D mammography; PowerLook, a density assessment solution; and ProFound Risk, a breast cancer risk analysis. The company was formerly known as Howtek, Inc. and changed its name to iCAD, Inc. in June 2002. iCAD, Inc. was incorporated in 1984 and is headquartered in Nashua, New Hampshire.
Market Cap
$47.6M
Volume
187.7K
Cash and Equivalents
$17.2M
EBITDA
-$5.5M
Tax Rate Collected
N/A
Tax Rate Ratio
N/A
Gross Profit
$17.0M
Profit Margin
86.78%
52 Week High
$3.78
52 Week Low
$1.18
Dividend
N/A
Price / Book Value
1.61
Price / Earnings
-8.21
Price / Tangible Book Value
2.28
Enterprise Value
$30.7M
Enterprise Value / EBITDA
-5.90
Operating Income
-$6.1M
Return on Equity
18.09%
Return on Assets
-9.63
Cash and Short Term Investments
$17.2M
Debt
$362.0K
Equity
$28.7M
Revenue
$19.6M
Unlevered FCF
-$3.3M
Sector
Health Care Technology
Category
N/A
Hedge Funds that own this stock
PREMIUM
Upgrade to Yellowbrick Premium to unlock the Professional Funds that own this company (and many other perks).
Upgrade to Yellowbrick PremiumYellowbrick Portfolios that own this stock
PREMIUM
Upgrade to Yellowbrick Premium to unlock the Yellowbrick portfolios that own this company (and many other perks).
Upgrade to Yellowbrick Premium